Introduction {#sec1-1}
============

Thrombolytic drugs are used to treat a variety of venous and arterial thromboembolic complaints, especially acute myocardial infarction.\[[@ref1]\] These agents are generally plasmin activators which can convert plasminogen to plasmin. The fibrinolytic action of plasmin dissolves insoluble fibrin clots.

Thrombolytic agents can be classified in several ways. One general classification is according to fibrin specificity. Nonfibrin-specific agents comprise streptokinase and urokinase, fibrin-specific agents comprise tissue plasminogen activator (tPA), and next generations agents include reteplase, tenecteplase, monteplase, lanoteplase, pamiteplase, desmoteplase (Bat-PA), and chimeric thrombolytics. The drug tPA is the first Food and Drug Administration (FDA)-approved drug from this category. Agents such as reteplase and tenecteplase were created from tPA to modify the efficacy and safety. These new generation thrombolytic benefits such as a prolonged half-life and increased resistance, inhibition by plasminogen activator inhibitors, and increased fibrin specificity have been developed. Reteplase has been approved in Europe and the United States in 1996. According to the Iran FDA, reteplase is available in Iran as powder for solution parenteral containing 10.4 units costing about 5,250,000 rials with an annual sale of 40 vials and also as single-use vial (10 unit/10 ml) costing about 460,000 rials with an annual sale of 31,830 vials. In this review, reteplase is assessed in terms of its structure, function, expression, and production.

Structure of Reteplase {#sec1-2}
======================

Reteplase is a single-chain deletion mutant of tPA containing 355 amino acids (starting with serine and ending with proline). The tPA molecule comprises five separate structural domains. The zymogen enzyme exists as a single chain, but in the presence of plasmin, it can be cleaved into activated heavy and light chain forms. The heavy chain comprises four domains: a finger domain that is homologous to a part of fibronectin, a growth factor domain that is homologous to the epidermal growth factor, and two unequal kringle domains. The light chains include the serine protease domain, which is homologous to trypsin and chymotrypsin.

Plasmin cleavage occurs at Arg278 in the C-terminal of the kringle-2 domain and produces the two-chain form of tPA. Reteplase comprises the C-terminal kringle-2 and serine protease domains of tPA that lacks valine-4 through the glutamate-175 residue \[[Figure 1](#F1){ref-type="fig"}\]. Its total molecular weight is 39 kDa and it has nine disulfide bonds in its structure.\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7]\] The reteplase molecule has three potential N-glycosylation sites which are Asn-12, Asn-48, and Asn-278, respectively.\[[@ref8]\] Because the presence of carbohydrate side chains in the structure of reteplase is not necessary for its function, this protein can be expressed in *Escherichia coli*.

![Tissue plasminogen activator and reteplase schematic figure](ABR-8-19-g001){#F1}

Function and Thrombolytic Action of Reteplase {#sec1-3}
=============================================

The kringle-2 domain is implicated in binding to fibrin as well as attachment to cytokeratin-8 and endothelial cell surface binding sites. In the protease domain, the functional regions are amino acids 176--527 and 1--3 from the N-terminal.\[[@ref6][@ref9][@ref10][@ref11][@ref12][@ref13]\] In contrast to tPA, the epidermal growth factor and fibronectin finger domains are absent in reteplase. The results of these deletions are extended plasma half-life, reduced fibrin specificity,\[[@ref13]\] and the ability to penetrate into blood clots.\[[@ref4][@ref14]\] Reteplase and tPA do not differ with regard to inhibition by plasminogen activator inhibitor-1 (PAI-1).\[[@ref15]\]

The thrombolytic action of reteplase, as for tPA, catalyzes the conversion of the inactive proenzyme plasminogen into the active protease plasmin, which cleaves the Arg-Val bond. This action degrades the fibrin matrix of the thrombus\[[@ref16]\] \[[Figure 2](#F2){ref-type="fig"}\]. In the absence of fibrin, reteplase shows plasminogen activator activity similar to that of tPA, but its binding affinity to fibrin is lower than that of tPA (about 5-fold) due to the deletion of the fibronectin finger region.\[[@ref9]\] In the presence of fibrin, the kringle-2 domain is known to stimulate protease activity, but this effect is lower in reteplase than in tPA. This indicates that the fibronectin finger is involved in the stimulation of protease activity in this enzyme.\[[@ref15]\] Like tPA, during fibrinolysis, reteplase can be converted into a double-chain form.\[[@ref3]\]

![Thrombolytic action of plasminogen activators](ABR-8-19-g002){#F2}

Production of Reteplase {#sec1-4}
=======================

Suitable host {#sec2-1}
-------------

Reteplase has been expressed in hosts such as *Bacillus subtilis*,\[[@ref17]\] seaweed such as *Laminaria japonica*,\[[@ref18]\] yeast such as *Pichia methanolica*\[[@ref19]\] and *Pichia pastoris*,\[[@ref20][@ref21]\] and insect cells.\[[@ref22]\] The expression levels of reteplase vary significantly among all these systems with problems in protein instability. While literature exists about the expression of reteplase in bacterial systems such as *E. coli*,\[[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29]\] some studies about recombinant production of reteplase in *E. coli* have not been published and the details of some experimental methods are not available.\[[@ref29]\]

*E. coli* is currently considered to be the most widely used host organism for biopharmaceutical production of heterologous recombinant proteins. The expression system of *E. coli* is desirable because of its ability to quickly reach high cell density, its simplicity, low cost, and FDA approval for human applications.\[[@ref30][@ref31]\] Production of reteplase in *E. coli* remains a challenge. The presence of several disulfide bonds, its rare codon usage, and cytotoxicity are major drawbacks to reteplase expression in *E. coli*.\[[@ref31][@ref32]\] Fathi-Roudsari *et al*. assessed three *E. coli* strains (*E. coli* BL21 \[DE3\], Rosetta-gami \[DE3\], and SHuffle T7) for reteplase production. Their results suggest that BL21 (DE3) has the highest level of the expression of this protein, followed by Rosetta-gami (DE3) and Shuffle T7.\[[@ref33]\]

Production strategy {#sec2-2}
-------------------

Protein production in *E. coli* can be performed intracellularly (in the form of a soluble protein or inclusion body \[IB\]) and extracellularly (expressed in periplasmic space). The intercellular production of recombinant proteins has benefits over extracellular production. For example, it eludes proteolysis with periplasmic proteases and leads to continuous recombinant protein production.\[[@ref34][@ref35]\]

### Intracellular production of reteplase {#sec3-2}

Although it is expressed intracellularly, reteplase cannot be folded appropriately into the *E. coli* cytoplasm but is accumulated as IBs.\[[@ref32]\] This is caused by the disulfide bonds in reteplase; thus, it requires a refolding process. Fathi-Roudsari *et al*. used BL21 (DE3), Rosetta-gami (DE3), and SHuffle T7 for reteplase expression. SHuffle T7 is a genetically engineered *E. coli* strain that is appropriate for soluble production of disulfide-bonded proteins. Rosetta-gami B (DE3) is suitable for improving the expression of eukaryotic proteins in *E. coli* by overcoming codon bias. This strain increases disulfide bond formation in the cytosolic fraction because of trxB and gor gene mutations.\[[@ref33]\]

They reported that, despite an alteration of expression conditions such as a decrease in temperature and a change in oxygen supply and inducer concentration, the oxidizing cytoplasm of Rosetta-gami and SHuffle could not be used for soluble production of reteplase. During the formation of IBs, which are completely insoluble, several folding intermediates also form. It appears that, in the folding intermediates, some disulfide bonds are created between correct cysteine pairs. The cytoplasms of engineered Rosetta-gami and SHuffle T7 can increase the folding intermediates of reteplase in the IBs. During renaturation, these folding intermediates will quickly transit to the native state of the proteins, so the yield of refolding will increase.\[[@ref36][@ref37][@ref38]\] Fathi-Roudsari *et al*. reported that the lower concentration of reteplase gained from Rosetta-gami and SHuffle T7, in comparison with the higher concentrations of BL21, can provide an appropriate yield from refolding.\[[@ref33]\]

Zhao *et al*. reported the reteplase cloning and expression in *E. coli* using the pET22b vector and an immovable experimental setting (1-mM Isopropyl β-D-1-thiogalactopyranoside \[IPTG\], 37°C, shaken for 14 h at 150 rpm) as IB.\[[@ref6]\] Studies have tried to increase the expression and production of reteplase. Shafiee *et al*. examined the effect of conditions such as IPTG concentration, temperature, shaking speed, and glucose concentration on the reteplase expression in *E. coli* cells as IBs. They reported that maximum protein production was obtained with the addition of 1-mM IPTG at 37°C and 100 rpm of shaking in the absence of glucose.\[[@ref4]\]

One parameter that influences the high expression of protein in *E. coli* is the type of promoter. One of the strongest promoters in *E. coli* is the tac promoter and a hybrid of trp and lac promoters with an efficacy that is 2--3 times greater than for trp and 7 times greater than lacUV5 promoters. This promoter can be repressed by the lac repressor and induced by IPTG.\[[@ref39][@ref40][@ref41]\] Aghaabdollahian *et al*. used the pGEX-5x-1 plasmid with the tac promoter for expression of reteplase in *E. coli* TOP10. They successfully cloned and expressed reteplase using the tac promoter in the pGEX-5x-1 expression vector, which is a suitable selection for the optimization of the expression of reteplase in *E. coli*.\[[@ref42]\] In the presence of the GST sequence at the beginning of the insert, the pGEX-5x-1 expression vector creates a pGEX GST fusion protein system, which is commonly used for high-level expression for rapid and efficient purification of fusion proteins expressed in bacterial lysates.\[[@ref43][@ref44]\]

Promoters (lac, tac, T7, and arabinose) have been compared in terms of reteplase expression in *E. coli*. After refolding and activity assays of the produced reteplase, the best results related to the arabinose promoter.\[[@ref45]\] For IBs, refolding is necessary to achieve an active protein. Because reteplase has nine disulfide bonds, refolding can be performed by oxidizing/reducing glutathione. This method is used routinely in many studies.\[[@ref4][@ref46][@ref47][@ref48]\] In a comparative investigation, Liu *et al*. produced reteplase with thioredoxin as a fusion protein (Trx-r-PA). They reported a refolding strategy that included the posttreatments of solubilized Trx-r-PA IBs, on-column refolding by size-exclusion chromatography using three gel types, and urea gradient and two-stage temperature control in refolding. They finally removed the Trx-tag by digestion with enterokinase.\[[@ref49]\]

Zhao *et al*. used protein disulfide isomerase (PDI) for reteplase refolding and claimed that their study was the first to apply PDI to succor protein folding of the nine disulfide bonds. They employed reteplase purification with two-step chromatography including lysine-affinity chromatography and CM-sepharose cation-exchange chromatography and reported over 5 × 10^5^ IU/mg specific activity of the purified reteplase.\[[@ref6]\] Zhuo *et al*. suggested that disulfide bonds are the major obstacle to proper folding of this protein and the creation of an IB. They used DsbA/DsbC foldases to enhance soluble expression of recombinant reteplase in *E. coli* for the first time. DsbA and DsbC simplified protein folding by catalyzing the construction and isomerization of disulfide bonds. Moreover, DsbA shows molecular chaperone activity; thus, Zhuo *et al*. achieved soluble expression of reteplase. Their results from the fluorescence spectra showed that the structural conformation of soluble reteplase was similar to its native state and they reported 2.35 × 10^5^ IU/mg thrombolytic activity for this produced reteplase.\[[@ref50]\]

Fathi-Roudsari *et al*. investigated optimization of the auto-induction procedure for reteplase expression in a soluble and active form in *E. coli*. They reported that the use of an auto-induction strategy at 37°C showed that Rosetta-gami (DE3) had the maximum level of active and soluble reteplase production compared to the *E. coli* strains of BL21 (DE3) and Shuffle T7. They said that temperature predominantly influenced the level of active reteplase production. In other words, decreasing the temperature to 25°C and 18°C improved the level of active reteplase by 20% and 60%, respectively. Another factor that affected the active production of reteplase in cytoplasm, they reported, is the composition of the auto-induction medium. The use of more highly enriched auto-induction medium with a super broth base that included trace elements considerably increased the biologically active reteplase by 30%.\[[@ref51]\]

### Extracellular production of reteplase {#sec3-3}

The secretory production of recombinant proteins in *E. coli* has been used for the production of pharmaceutical proteins.\[[@ref34][@ref52]\] Compared with cytoplasmic production, targeting of the expressed protein in periplasmic space or by the culture medium simplifies downstream processing and reduces production costs.\[[@ref53]\] Two studies expressed reteplase in *E. coli* TOP10 with pBAD/gIIIA vector. This vector allows secretion of the expressed protein into periplasmic space. In these studies, low amounts of the expressed reteplase were detected in the periplasmic space. Most of them were present as IBs inside the cell. It has been reported that this might be due to the high expression of proteins which affect the export mechanisms of cells for sending recombinant proteins into periplasmic space.\[[@ref48][@ref54]\]

Chen *et al*. provided a strategy for the construction of leaky strains for the extracellular production of the target proteins.\[[@ref55]\] Leaky strains can be created by knocking out the genes associated with the biosynthesis of the cell membranes and walls, particularly the outer membrane genes such as *lpp* encoding Braun\'s lipoprotein.\[[@ref56]\] In their study, genes such as *lpp* and *mrcB* (encoding peptidoglycan synthetase) mutated.\[[@ref57]\] Their results showed that mutants with in-frame single/double deletion of genes (*mrcB* and *lpp*) could not effectively leak reteplase due to protein expression in the cytoplasm. Khodabakhsh *et al*. compared the cytoplasmic and periplasmic production of reteplase. They reported that the cytoplasmic expression of reteplase was a more appropriate system for the expression of this protein and that high amounts of reteplase were obtained from the expressed protein in the form of IBs though it required an additional refolding step for activation.\[[@ref54]\]

Discussion {#sec1-5}
==========

Thrombolytic drugs are considered to be life-savers due to their action in dissolving thrombi and achieving reperfusion. Nevertheless, its immunogenicity, fibrin specificity, half-life, and the cost of treatment are determining factors that influence the use of such drugs. There is an ongoing need for developing novel molecules at lower costs to solve these problems.

In the developed countries, tPA is commonly used while, in developing countries, streptokinase remains the drug of choice for thrombolytic therapy because it is less expensive.\[[@ref58]\] Because this medication is not fibrin specific, it can cause the breakdown of circulating fibrinogen, which will considerably affect hemostasis.\[[@ref59]\] The use of recombinant DNA technology and optimized bioprocessing strategies can help to develop new drugs and reduce costs.

Conclusion {#sec1-6}
==========

Reteplase is a thrombolytic drug that is a nonglycosylated derivation of tPA. Its production can be achieved in *E. coli*; thus, the cost of production is less than that of other expression systems, such as mammalian cells. With the use of the optimized production conditions such as the utilization of the best host strain, expression, and purification strategies, optimal production of this drug can be achieved.
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